Due Diligence Materials

1.1 Global Embolization Particle Market Research Report (Market Research Future)
PASSWORD REQUIRED
Global Embolization Particle Market Rese[...]
Adobe Acrobat document [4.4 MB]

1.2 Update Global Embolization Particle Sales Market Report (QY Research)
QY Research - Update Global Embolization[...]
Adobe Acrobat document [3.4 MB]

2.1 Ekobi Publication - Owen et al, 2012
NOTE: The product was originally named Occlusin 500... it was rebranded to Ekobi® Embolization Microspheres
Owen et al, 2012 - Occlusin : Ekobi - Re[...]
Adobe Acrobat document [590.2 KB]

2.2 CIRSE Presentation 2018 - Ekobi Ultrasound & PAE - Dr. Owen
CIRSE Presentation 2018 - Ultrasound PA[...]
Adobe Acrobat document [937.1 KB]

2.3 Ekobi Presentation - CIO 2020 - Dr. E. St. Amour - Feasibility and Safety of a Novel Bland Embolization Using Ekobi Embolization Microspheres in an Office Based Laboratory
CIO Abstract 2020 (St. Amour).pdf
Adobe Acrobat document [111.3 KB]

2.4 GEST Abstract 2020 - Dr. Richard Owen - Prospective Uterine Artery Embolization Study Using Biodegradable, Echogenic Microspheres
GEST Abstract 2020 - Prospective UAE Stu[...]
Adobe Acrobat document [100.3 KB]

2.5 Ekobi Usage Presentation (GAE, PAE, UAE/UFE, Product Preparation) - Video - Dr. Darshan Bakshi 2022
EKOBI Presentation Dr. Darshan Bakshi - [...]
QuickTime video format [41.5 MB]

3.1 News Story - Ekobi - Global News (Health Matters Section) - Su Ling Goh
V8-Global Health Matters - News Cast - E[...]
QuickTime video format [38.1 MB]

3.2 Ekobi Video - Global News Patient Interview - Post-treatment
Ekobi - Patient Interview - Global News [...]
QuickTime video format [43.3 MB]

3.3 CADTH - Issue 182, 2020 - Ekobi - Minimally Invasive Treatments for LUTS due to BPH
CADTH - Issue 182, Feb 2020 - Minimally [...]
Adobe Acrobat document [721.9 KB]

3.4 Ekobi Prostate Artery Embolization (PAE) Description - Patient Interview Post-treatment
V1-Canadian Prostate BPH Embo Video.mov
QuickTime video format [76.9 MB]

3.5 Ekobi Uterine Fibroid Embolization (UFE) Description - Video
V2-Canadian Uterine Fibroid Embo Video.m[...]
QuickTime video format [76.1 MB]

3.6 Ekobi Uterine Fibroid Embolization - Patient Interview
V3-Ekobi Uterine Fibroid Patient Intervi[...]
QuickTime video format [92.1 MB]

3.7 Uterine Fibroid Embolization (real-time) - Ekobi 504 and Ekobi 505
V4-Ekobi vs Competition - Real Time Vide[...]
QuickTime video format [1.6 MB]

3.8 IMBiotechnologies Company Overview - Video
V7- IMBiotechnologies and How Ekobi Work[...]
QuickTime video format [70.1 MB]

4.1 IMBio Cap Table
IMBio - Cap Table (Pre-Money Go Public).[...]
Adobe Acrobat document [414.7 KB]

5.1 Michael Stewart - CV
Michael Stewart CV - 2023.pdf
Adobe Acrobat document [247.6 KB]

5.2 Irwin Griffith - CV
Irwin Griffith - CV 2023.pdf
Adobe Acrobat document [278.3 KB]

5.3 Ruth Collins-Nakai - CV
Ruth Collins-Nakai - RESUMÉ.pdf
Adobe Acrobat document [84.7 KB]

5.4 Douglas Deeth - CV
Douglas Deeth - CV 2023.pdf
Adobe Acrobat document [75.7 KB]

7.1 Clinical Study Report OCL503-P1-UFE-01 (Fibroid Study 1)
CSR OCL503-P1-UFE-01.pdf
Adobe Acrobat document [740.2 KB]

7.2 Clinical Study Report - OCL500-P3-02 2 (Fibroid Study 2)
Clinical Study Report - CSR OCL500-P3-UF[...]
Adobe Acrobat document [4.4 MB]

7.3 Clinical Study Report OCL-500-CLN-003 (Prostate Study)
CSR OCL-500-CLN-003.0 PAE .pdf
Adobe Acrobat document [935.5 KB]

7.4 Preclinical Study Report OCL-PRE-001.2 (Porcine)
Report OCL-PRE-001.2 (porcine).pdf
Adobe Acrobat document [2.3 MB]

7.5 Preclinical Study Report OCL-PRE-002.2 (Ovine)
Report OCL-PRE-002.2 (ovine).pdf
Adobe Acrobat document [4.4 MB]

7.6 Biocompatibility - Genotoxicity: Bacterial Reverse Mutation Study (saline extract) - Report V0023_211
ISO 10993 Part 3 - Tests for Genotoxicity, Carcinogenicity, and Reproductive Toxicity
Genotoxicity - Bact Rev Mut (saline).pdf
Adobe Acrobat document [6.8 MB]

7.7 Biocompatibility - Genotoxicity: Bacterial Reverse Mutation (DMSO extract) - Report V0023_211
ISO 10993 Part 3 - Tests for Genotoxicity, Carcinogenicity, and Reproductive Toxicity
Genotoxicity - Bact Rev Mutation.pdf
Adobe Acrobat document [7.0 MB]

7.8 Biocompatibility - Genotoxicity: Mouse Peripheral Blood Micronucleus - Report T0566_500, T0566_501
ISO 10993 Part 3 - Tests for Genotoxicity, Carcinogenicity, and Reproductive Toxicity
Genotoxicity - Mouse Periph Bld Micronuc[...]
Adobe Acrobat document [9.4 MB]

7.9 Biocompatibility - Genotoxicity: Mouse Lymphoma Mutagenesis - Report 07-3193-G1
ISO 10993 Part3 - Tests for Genotoxicity, Carcinogenicity, and Reproductive Toxicity
Appendix 15-9 ISO Mouse Lymph Mutagenesi[...]
Adobe Acrobat document [3.9 MB]

7.10 Biocompatibility - Blood Interactions: ASTM Hemolysis - Report V0607_100
ISO 10993 Part 4 - Tests for Interactions with Blood
ASTM Hemolysis.pdf
Adobe Acrobat document [6.6 MB]

7.11 Biocompatibility - Blood Interactions: SC5b-9 Complement Activation - Report V0639_000
ISO 10993 Part 4 - Tests for Interaction with Blood
SC5b-9 Complement Activation.pdf
Adobe Acrobat document [506.2 KB]

7.12 Biocompatibility - Blood Interactions: C3a Complement Activation - Report V0022_000
ISO 10993 Part 4 - Tests for Interactions with Blood
C3a Complement Activation.pdf
Adobe Acrobat document [506.6 KB]

7.13 Biocompatibility - Cytotoxicity ISO Agarose Overlay (solid) - Report V0015_110
ISO 10993 Part 5 - Tests for in vitro Cytotoxicity
Cytotoxicity - ISO Agarose Overlay.pdf
Adobe Acrobat document [4.2 MB]

7.14 Biocompatibility - Cytotoxicity ISO Elution (MEM extract) - Report V0014_130
ISO 10993 Part 5 - Tests for in vitro Cytoxicity
Cytotoxicity - ISO Elution (MEM).pdf
Adobe Acrobat document [3.8 MB]

7.15 Biocompatibility - Muscle Implantation (4 weeks) - Report T1250_804
ISO 10993 Part 6 - Tests for Local Effects After Implantation
Biocompatibility - ISO Muscle Implantati[...]
Adobe Acrobat document [6.0 MB]

7.16 Biocompatibility - Muscle Implantation (12, 24 weeks) - Report T1250_812/S
ISO 10993 Part 6 - Tests for Local Effects After Implantation
Biocompatibility - ISO Muscle Implantati[...]
Adobe Acrobat document [7.6 MB]

7.17 Biocompatibility - Intracutaneous - Report T1251_800
ISO 10993 Part 10 - Tests for Skin Sensitization
Biocompatibility ISO Intracutaneous Stud[...]
Adobe Acrobat document [4.5 MB]

7.18 Biocompatibility - Hypersensitivity: ISO Maximization Sensitization Study (extract) - Report T1261_300
ISO 10993 Part 10 - Tests for Irritation and Delayed-type Hypersensitivity
ISO Max Sensitization.pdf
Adobe Acrobat document [6.2 MB]

7.19 Biocompatibility - Two Week Toxicity (rat, parenteral, two extracts) - Report TS200_901
ISO 10993 Part 11 - Tests for Systemic Toxicity
Appendix 15-6 2wk Tox Rat Parenteral.pdf
Adobe Acrobat document [12.6 MB]

7.20 Biocompatibility - USP Pyrogen Study (material mediated) - Report TU10_807
ISO 10993 Part 11 - Tests for Systemic Toxicity
Material Mediated Pyrogen.pdf
Adobe Acrobat document [1.4 MB]

8.1.1 Ekobi PCT CA2008-002060
PCT CA2008:002060 - WO2009067791A4.pdf
Adobe Acrobat document [147.2 KB]

8.1.2 Ekobi PCT CA2018/051092 - WO 2019046955 - Sono-Responsive Embolic Agents
WO2019046955-APBDY-20190314-3123.pdf
Adobe Acrobat document [4.5 MB]

8.1.3 - In-Licensed PCT 2007:022885 - Spheronized Polymer Particles (Evonik)
PCT US2007:022885 - Spheronized Polymer [...]
Adobe Acrobat document [3.2 MB]

8.1.4 Issued and Pending Patent Summary
IMBio IP Summary.pdf
Adobe Acrobat document [38.6 KB]

8.1.5 Trademark Summary
IMBio Trademark Summary.pdf
Adobe Acrobat document [32.6 KB]

9.1 Ekobi Manufacturing Request for Proposal (template)
Ekobi Manufacturing RFP 2023.pdf
Adobe Acrobat document [551.6 KB]

9.2 Master Product Validation Plan (SOP-030)
SOP-030 - Master Product Validation Plan[...]
Adobe Acrobat document [174.4 KB]

10.1 Forecast - IMBIO 5-Year Model (self-funded)
IMBIO - 5-Year Model (self-funded).xlsx
Microsoft Excel sheet [202.0 KB]